Comparison of two adjuvant high-dose rate vaginal cuff brachytherapy dose fractionation regimens for treatment of early-stage uterine cancer

Files

Authors

Catherine Raciti, Oakland University William Beaumont School of Medicine Medical Student
Hong Ye, Corewell Health East
Allison J. Hazy, Corewell Health East Resident
Maha Saada Jawad, Corewell Health East

Description

• Endometrial cancer is the most common gynecologic malignancy in the United States, with peak incidence at 63 years of age.¹

• PORTEC-2 trial established VBT alone as an effective modality for select high-intermediate risk patients.2

• There was no strict ABS guideline for dose fractionation; our institution adopted a 30Gy in 6 fractions regimen based on radiobiological calculations.3,4

• COVID-19 pandemic led to a shift towards 22Gy in 4 fractions

• Objective: Compare oncologic outcomes and toxicity between the 30Gy/6fx and 22Gy/4fx regimens.

• Hypothesis: Both regimens are well-tolerated and equally effective.

• Impact: Findings will inform clinical practice and guide future treatment protocols for early-stage endometrial cancer.

Publication Date

5-2025

Disciplines

Oncology | Radiation Medicine

Recommended Citation

Raciti C, Ye H, Hazy AJ, Jawad MS. Comparison of two adjuvant high-dose rate vaginal cuff brachytherapy dose fractionation regimens for treatment of early-stage uterine cancer. Poster presented at: Oakland University William Beaumont School of Medicine Embark Capstone Colloquium; 2025 May; Rochester Hills, MI.

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2025.